NCT07237737

Brief Summary

To determine if there is a difference in wound healing and surgical site infection (SSI) rates using the Alexis wound retractor vs. not using it in longitudinal direct anterior approach total hip arthroplasty.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
202

participants targeted

Target at P75+ for not_applicable

Timeline
13mo left

Started Dec 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 15, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 20, 2025

Completed
1 year until next milestone

Study Start

First participant enrolled

December 1, 2026

Expected
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2028

Last Updated

February 5, 2026

Status Verified

February 1, 2026

Enrollment Period

1.1 years

First QC Date

November 15, 2025

Last Update Submit

February 3, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Number of Days to Identification of Delayed Wound Healing

    Delayed wound healing is defined as the presence of one or more of the following clinical signs: drainage from wound, wound dehiscence, and superficial surgical site infection. Assessment is performed by clinical examination and documentation in the postoperative period. The outcome is measured in number of days from surgery to identification of delayed healing

    Up to 14 days

  • Patient satisfaction with scaring as measured by Patient Scar Assessment Scale

    Using the Patient Scar Assessment Scale, which is a validated plastic surgery tool for evaluating scars from the patient's perspective. Measured with a scale from 0 to 10, higher score indicates less satisfaction.

    Up to 12 months

  • Scar cosmesis as measured by Observer Scar Assessment Scale

    Using the Observer Scar Assessment Scale, which is a validated plastic surgery tool for evaluating scars from the observer perspective. Measured with a scale from 0 to 10, higher score indicates worse scar cosmesis.

    Up to 12 months

Secondary Outcomes (5)

  • Number of Participants Reporting Lateral Femoral Cutaneous Nerve (LFCN) Symptoms

    Up to 6 months

  • Hip Disability and Osteoarthritis Outcome Score (HOOS) - Patient-Reported Outcome

    Up to 12 months

  • Number of Intraoperative fractures

    Up to 3 hours (duration of surgery)

  • Length of surgery

    Up to 3 hours

  • Number of Postoperative Complications

    Up to 90 days

Study Arms (2)

Alexis Retractor

EXPERIMENTAL

Subjects in this arm will undergo surgery using the Alexis wound retractor.

Device: Alexis wound retractor

Non-Alexis Retractor

ACTIVE COMPARATOR

Subjects in this arm will undergo surgery using a standard retractor that does not include the Alexis device.

Device: Standard wound retractor

Interventions

A conventional surgical retractor used during procedures without the features of the Alexis device

Non-Alexis Retractor

A surgical device used to retract tissue during procedures, designed to reduce wound trauma and improve healing

Alexis Retractor

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing primary unilateral longitudinal direct anterior approach total hip arthroplasty
  • Patients undergoing primary total hip arthroplasty

You may not qualify if:

  • Patients with history of prior open surgery on the affected hip
  • Patients with history of prior total hip arthroplasty on the contralateral hip
  • Patients with allergies or absolute contraindication to standardized drugs administered within the University of Miami protocol for total hip replacement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami

Miami, Florida, 33125, United States

Location

MeSH Terms

Conditions

Osteoarthritis, Hip

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Victor H Hernandez, MD, MSc

    University of Miami Department of Orthopaedics

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Natalia Cruz, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Orthopaedic Surgery

Study Record Dates

First Submitted

November 15, 2025

First Posted

November 20, 2025

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Last Updated

February 5, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations